New treatment option for Erector Spinae Plane Block
Official title Continuous ESP Block in Patients Undergoing CABG Surgery.
ClinicalTrials.gov ID: NCT07666178
What this study is testing
What is Ropivacaine?
Ropivacaine is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for erector spinae plane block.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study addresses articles and studies related to the erector spinae plane (ESP) block and its technique, advantages and disadvantages, applicability, among others. It aims to provide more information about this block, which is relatively new, and how it can be explored in the anesthesiologist's routine, mainly inserted in the anesthesia scenario for cardiac surgery with a focus on postoperative analgesia.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- Consent to the free and informed consent term.
- Patient undergoing coronary artery bypass graft surgery with cardiopulmonary bypass (CPB).
- Preserved left ventricular global function (LVEF \> 50%).
You likely can't join if
- Moderate or severe valvular dysfunction.
- Previous anterior sternotomy.
- Known allergy to the study drugs.
- Complications during catheter insertion or block placement.
- Pre-existing diagnosed chronic pain under treatment.
- Concomitant use of drugs with a long half-life (induction and anesthetic maintenance doses will be standardized; patients taking medications with a...
See the full eligibility criteria
- Consent to the free and informed consent term.
- Patient undergoing coronary artery bypass graft surgery with cardiopulmonary bypass (CPB).
- Preserved left ventricular global function (LVEF \> 50%).
- Moderate or severe valvular dysfunction.
- Previous anterior sternotomy.
- Known allergy to the study drugs.
- Complications during catheter insertion or block placement.
- Pre-existing diagnosed chronic pain under treatment.
- Concomitant use of drugs with a long half-life (induction and anesthetic maintenance doses will be standardized; patients taking medications with a long half-life are excluded to prevent bias in outcome assessment).
- Concomitant administration of Magnesium Sulfate.
The study team makes the final eligibility decision.
Where it's taking place
- São Paulo, São Paulo, Brazil
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include São Paulo, São Paulo, Brazil. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.